Scalp-Injected RNA Hair Loss Drug Completes Phase 1b Dosing in Australia
OliX announced on August 4 that it has completed patient dosing in the Australian Phase 1b clinical trial for OLX104C (compound name: OLX72021), an...
Search results for "cell therapy"
Timing of Immune Cell Entry Dictates Anti-Cancer Defense in Hard-to-Treat Brain Tumors
Some immune cells surrounding a tumor actively attack it, while others create conditions that help it survive.
Prevention vs. Treatment: Why Cancer Therapy Demands a Completely Different Diet
What makes diabetes particularly dangerous is the risk of severe, systemic complications.
Novartis Halts Lu-NeoB Development After Early Clinical Data Fall Short
Novartis has discontinued the development of Lu-NeoB, an experimental cancer therapy designed to seek out tumor cells...
The Blood Cancer Decoy: Why Some Lymphoma Patients Stop Responding to Treatment
For patients diagnosed with aggressive blood cancers, receiving a proven targeted therapy offers a clear path toward a...
Placebo Outperforms TG-C: Data Errors and Stock Volatility Cloud Kolon TissueGene’s Phase 3 Trial
Kolon TissueGene’s knee osteoarthritis cell and gene therapy, TG-C, has failed to achieve statistical significance on...
EZH1 Mutation 'Locks' Cancer-Fighting Genes to Fuel Thyroid Tumors, Study Finds
Cancer cells do not grow simply by switching on genes that drive proliferation; they can also lock away genes that keep...
Celltrion Files for EU Approval of Cosentyx Biosimilar CT-P55, Targeting $6.7 Billion Autoimmune Market
Celltrion announced on the 24th that it has submitted a marketing authorization application to the European Medicines...
Korea University Anam Hospital Logs 8,000 Atrial Fibrillation Procedures, a First in South Korea
Korea University Anam Hospital has achieved a cumulative total of 8,000 atrial fibrillation procedures—a nationwide...
GSK Wins Early FDA Approval for Oral Lung Cancer Drug Jideytro Following $10.6 Billion Nuvalent Acquisition
A new oral therapy is now available for patients with ROS1-positive lung cancer whose disease has progressed following...